Listed

Nervgen Pharma Corp.

NGENNasdaqCIK 1751912HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Balance sheet

Cash and equivalentsCAD 22.1m, FY2025
Shareholders' equityCAD 3.5m, FY2025
Line itemUnitperiod not labelled2023-12-31period not labelled2024-12-31FY20252025-12-31
Cash and equivalents$m11.7Cash and equivalents, period not labelled, at 2023-12-31CAD 11.7m. XBRL concept ifrs-full:CashAndCashEquivalents. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure17.3Cash and equivalents, period not labelled, at 2024-12-31CAD 17.3m. XBRL concept ifrs-full:CashAndCashEquivalents. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure22.1Cash and equivalents, FY2025, at 2025-12-31CAD 22.1m. XBRL concept ifrs-full:CashAndCashEquivalents. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure
Current assets$mnot reported19.0Current assets, period not labelled, at 2024-12-31CAD 19.0m. XBRL concept ifrs-full:CurrentAssets. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure22.8Current assets, FY2025, at 2025-12-31CAD 22.8m. XBRL concept ifrs-full:CurrentAssets. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure
Total assets$mnot reported19.5Total assets, period not labelled, at 2024-12-31CAD 19.5m. XBRL concept ifrs-full:Assets. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure23.2Total assets, FY2025, at 2025-12-31CAD 23.2m. XBRL concept ifrs-full:Assets. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure
Current liabilities$mnot reported16.9Current liabilities, period not labelled, at 2024-12-31CAD 16.9m. XBRL concept ifrs-full:CurrentLiabilities. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure19.7Current liabilities, FY2025, at 2025-12-31CAD 19.7m. XBRL concept ifrs-full:CurrentLiabilities. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure
Total liabilities$mnot reported16.9Total liabilities, period not labelled, at 2024-12-31CAD 16.9m. XBRL concept ifrs-full:Liabilities. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure19.7Total liabilities, FY2025, at 2025-12-31CAD 19.7m. XBRL concept ifrs-full:Liabilities. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure
Shareholders' equity$m(2.0)Shareholders' equity, period not labelled, at 2023-12-31−CAD 2.0m. XBRL concept ifrs-full:Equity. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure2.6Shareholders' equity, period not labelled, at 2024-12-31CAD 2.6m. XBRL concept ifrs-full:Equity. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure3.5Shareholders' equity, FY2025, at 2025-12-31CAD 3.5m. XBRL concept ifrs-full:Equity. 40-F filed 2026-03-31, accession 0001104659-26-037357.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.